Could CAR T-Cells tame MS? new trial launches
NCT ID NCT07006805
First seen Nov 01, 2025 · Last updated Jun 05, 2026 · Updated 27 times
Summary
This early-stage study tests a new treatment called CABA-201 for people with multiple sclerosis (MS). It uses a patient's own immune cells, modified to target and remove certain immune cells that may drive MS. The main goal is to check safety and find the right dose in 12 adults with relapsing or progressive MS.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.